Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Trial of Bexmarilimab and Nivolumab in Patients With Solid Tumours, Non-Small Cell Lung Cancer and Melanoma

NCT07718243 is registered in ClinicalTrials.gov with Institute of Cancer Research, United Kingdom as lead sponsor.

NCT NCT07718243
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07718243 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Trial of Bexmarilimab and Nivolumab in Patients With Solid Tumours, Non-Small Cell Lung Cancer and Melanoma
Lead sponsor
Institute of Cancer Research, United Kingdom
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 28, 2026
Completion date
January 31, 2030
Enrollment
62 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma (skin cancer), non small cell lung cancer, solid tumor in advanced stage